Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD

Impact of Cholecalciferol on Endothelial Fucntion and Blood Biomarkers in Patients With Chronic Kidney Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02005718

Enrollment

Registered

2013-12-09

Start date

2010-06-30

Completion date

2013-06-30

Last updated

2013-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKd Patients With Stage 3 and 4

Brief summary

Vitamin D deficiency is common in CKD and assciated with CV complications. Endothelial dysfucntion is common in CKD and is a harbinger of atherosclerosis. The study investigated the impact of Vitamin D on endothelial fucntion and blood biomarkers in CKD.

Interventions

DRUGCholecalciferol

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* CKD 3-4 Age 18-80

Exclusion criteria

* Recent MI, CVA, malignancy active infection active inflammation High calcium already on Viatmin D therapy

Design outcomes

Primary

Measure	Time frame
Flow mediated dilation	16 weeks

Secondary

Measure	Time frame
CD28 null cell frequency	16 weeks
Blood biomarkers of endothelial function and inflammation	16 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026